Palatable compositions including sodium phenylbutyrate and uses thereof
The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.
1. A pharmaceutical composition for oral administration of sodium phenylbutyrate comprising a plurality of layered particles having a volume-based particle size distribution in which at least 90% of the layered particles in the plurality of layered particles are smaller than 500 μm, wherein the layered particles comprise (i) a seed core; (ii) a drug layer comprising sodium phenylbutyrate; and (iii) a taste-mask coating comprising a polymer formed from dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate, wherein the pharmaceutical composition comprises about 10 to 20% by total weight of the seed core, greater than 60% by total weight sodium phenylbutyrate, and about 5% to 25% by total weight taste-mask coating.
2. The pharmaceutical composition of claim 1 , wherein the taste-mask coating is about 5 to 10% of the total weight.
3. The pharmaceutical composition of claim 1 , wherein the sodium phenylbutyrate comprises about 65% of the total weight.
4. The pharmaceutical composition of claim 1 , wherein the drug layer comprises sodium phenylbutyrate, a binder, and a plasticizer.
5. The pharmaceutical composition of claim 4 , wherein the binder is hydroxypropyl methylcellulose.
6. The pharmaceutical composition of claim 4 , wherein the plasticizer is polyethylene glycol having a molecular weight between 5,000 and 7,000.
7. The pharmaceutical composition of claim 1 , wherein the drug layer comprises about 65% by total weight sodium phenylbutyrate; 5 to 7% by total weight hydroxypropyl methylcellulose; and 0.1 to 1% by total weight polyethylene glycol having a molecular weight between 5,000 and 7,000.
8. The pharmaceutical composition of claim 1 , wherein the taste-mask coating further comprises a plasticizer and talc.
9. The pharmaceutical composition of claim 8 , wherein the plasticizer is polyethylene glycol having a molecular weight between 5,000 and 7,000.
10. The pharmaceutical composition of claim 1 , wherein the seed core comprises microcrystalline cellulose.
11. The pharmaceutical composition of claim 1 , further comprising about 8 to 10% by total weight hydroxypropyl methylcellulose.
12. The pharmaceutical composition of claim 1 , further comprising about 0.5 to 3% by total weight polyethylene glycol having a molecular weight between 5,000 and 7,000.
13. The pharmaceutical composition of claim 1 , wherein the taste-mask coating further comprises talc, and wherein the talc is less than about 4% by total weight.
14. The pharmaceutical composition of claim 1 , further comprising a seal coating between the drug layer and taste-mask coating.
15. The pharmaceutical composition of claim 14 , wherein the seal coating comprises about 1 to 5% by total weight of the composition.
16. The pharmaceutical composition of claim 14 , wherein the seal coating comprises a water soluble polymer.
17. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 65% by total weight sodium phenylbutyrate, 8 to 10% by total weight hydroxypropyl methylcellulose, 0.5 to 3% by total weight polyethylene glycol having a molecular weight between 5,000 and 7,000, 10 to 20% by total weight microcrystalline cellulose in the seed core, less than 4% by total weight of talc in the taste-mask coating, and 5 to 10% by total weight of the polymer formed from dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate.
18. The pharmaceutical composition of claim 1 , further comprising a glidant.
19. The pharmaceutical composition of claim 18 , wherein the glidant is silica.
20. The pharmaceutical composition of claim 1 , wherein, upon administration to a subject, the composition is bioequivalent to a sodium phenylbutyrate formulation that does not comprise a taste-mask coating.
21. The pharmaceutical composition of claim 1 , wherein the plurality of layered particles has a volume-based particle size distribution in which at least 90% of the layered particles in the plurality of layered particles are smaller than about 400 μm.
22. The pharmaceutical composition of claim 1 , formulated in unit dosage form.
23. The pharmaceutical composition of claim 1 , wherein the composition scores favorably in a taste test in comparison to a sodium phenylbutyrate formation that does not comprise a taste-mask coating.
24. The pharmaceutical composition of claim 1 , wherein, upon administration to a subject, the composition has greater sodium phenylbutyrate levels in the plasma at 30 minutes compared to a modified release formulation of sodium phenylbutyrate.
25. The pharmaceutical composition of claim 1 , wherein less than 15% of the sodium phenylbutyrate in the composition dissolves in a neutral pH over a period of 10 minutes.
26. The pharmaceutical composition of claim 1 , wherein at least 95% of the sodium phenylbutyrate in the composition dissolves at an acidic pH over a period of 60 minutes.
27. The pharmaceutical composition of claim 1 , wherein the composition is a powder or granules.